Cargando…
Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
BACKGROUND: Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain low globally. Availability of newer drugs has given scope to develop regimens that can be patient-friendly, less toxic, with improved outcomes. We proposed to determine the effectiveness of an entirely oral, sho...
Autores principales: | Padmapriyadarsini, Chandrasekaran, Vohra, Vikram, Bhatnagar, Anuj, Solanki, Rajesh, Sridhar, Rathinam, Anande, Lalitkumar, Muthuvijaylakshmi, M, Rana, Meera Bhatia, Jeyadeepa, Bharathi, Taneja, Gaurav, Balaji, S, Shah, Prashant, Saravanan, N, Chavan, Vijay, Kumar, Hemanth, Ponnuraja, Chinnayin, Livchits, Viktoriya, Bahl, Monica, Alavadi, Umesh, Sachdeva, K S, Swaminathan, Soumya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907500/ https://www.ncbi.nlm.nih.gov/pubmed/35767251 http://dx.doi.org/10.1093/cid/ciac528 |
Ejemplares similares
-
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021) -
Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2023) -
Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis
por: Ismail, N., et al.
Publicado: (2018) -
Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016) -
Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)